(VIANEWS) - BioNTech SE (BNTX), Afya (AFYA), California BanCorp (CALB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BioNTech SE (BNTX)
1145.1% sales growth and 133.85% return on equity
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
BioNTech SE's sales growth this year is anticipated to be 3227% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 12630.2%, now sitting on 7.77B for the twelve trailing months.
Volume
Today's last reported volume for BioNTech SE is 3261640 which is 4.08% below its average volume of 3400490.
BioNTech SE's sales growth is a negative 0% for the present quarter and 1145.1% for the next. The company's growth estimates for the current quarter and the next is 1188.8% and 438%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 133.85%.
Volatility
BioNTech SE's last day, last week, and last month's current intraday variation average was 3.28%, 7.23%, and 5.90%, respectively.
BioNTech SE's highest amplitude of average volatility was 7.10% (day), 9.68% (last week), and 8.18% (last month), respectively.
BioNTech SE's Stock Yearly Top and Bottom Value
BioNTech SE's stock is valued at $156.53 at 00:22 EST, way under its 52-week high of $464.00 and way higher than its 52-week low of $80.55.
BioNTech SE's Moving Average
BioNTech SE's value is way below its 50-day moving average of $269.93 and way below its 200-day moving average of $268.56.Previous days news about BioNTech SE(BNTX)
- According to MarketWatch on Thursday, 20 January, "The study involved a group of seven Germans visiting Cape Town in South Africa who had the first documented breakthrough cases of COVID between late November and early December after receiving three vaccine doses, including at least two of the mRNA shots developed by Pfizer with German partner BioNTech SE or Moderna . "
- According to Bloomberg Quint on Wednesday, 19 January, "Booster shots with messenger RNA vaccines such as those made by Pfizer Inc. and BioNTech SE failed to block omicron in a study of some of the first documented breakthrough cases caused by the highly contagious variant."
- According to Bloomberg Quint on Wednesday, 19 January, "Booster shots with mRNA vaccines such as those made by Pfizer Inc. and BioNTech SE failed to block infection with the omicron variant in the first study of its kind, South African researchers said."
2. Afya (AFYA)
20.6% sales growth and 9.71% return on equity
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil.
Afya's sales growth this year is anticipated to be 30.7% and 24.9% for next year.
Year-on-year quarterly revenue growth grew by 35.8%, now sitting on 1.42B for the twelve trailing months.
Volume
Today's last reported volume for Afya is 997722 which is 316.1% above its average volume of 239779.
Afya's sales growth for the next quarter is 20.6%. The company's growth estimates for the present quarter and the next is 20% and 33.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.71%.
Volatility
Afya's last day, last week, and last month's current intraday variation average was 0.98%, 1.87%, and 3.20%, respectively.
Afya's highest amplitude of average volatility was 9.90% (day), 5.93% (last week), and 5.87% (last month), respectively.
Afya's Stock Yearly Top and Bottom Value
Afya's stock is valued at $13.34 at 00:22 EST, way below its 52-week high of $28.23 and above its 52-week low of $12.62.
Afya's Moving Average
Afya's worth is way below its 50-day moving average of $16.50 and way under its 200-day moving average of $21.18.3. California BanCorp (CALB)
15.5% sales growth and 8.5% return on equity
California BanCorp operates as the bank holding company for California Bank of Commerce that provides commercial banking services to small to medium-sized businesses and professional firms in California.
California BanCorp's sales growth this year is expected to be 22.6% and 12.7% for next year.
Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 57.42M for the twelve trailing months.
Volume
Today's last reported volume for California BanCorp is 4475 which is 30% below its average volume of 6393.
California BanCorp's sales growth for the next quarter is 15.5%. The company's growth estimates for the current quarter and the next is 109.1% and 41.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.5%.
Volatility
California BanCorp's last day, last week, and last month's current intraday variation average was 2.88%, 2.20%, and 1.67%, respectively.
California BanCorp's highest amplitude of average volatility was 4.49% (day), 5.02% (last week), and 3.70% (last month), respectively.
California BanCorp's Stock Yearly Top and Bottom Value
California BanCorp's stock is valued at $21.00 at 00:22 EST, under its 52-week high of $22.50 and way higher than its 52-week low of $11.96.
California BanCorp's Moving Average
California BanCorp's value is above its 50-day moving average of $19.59 and way higher than its 200-day moving average of $18.20.4. TrueBlue (TBI)
12.2% sales growth and 9.02% return on equity
TrueBlue's sales growth this year is expected to be 15.2% and 8% for next year.
Year-on-year quarterly revenue growth grew by 43.7%, now sitting on 1.97B for the twelve trailing months.
Volume
Today's last reported volume for TrueBlue is 168092 which is 16.99% below its average volume of 202520.
TrueBlue's sales growth for the next quarter is 12.2%. The company's growth estimates for the ongoing quarter and the next is 145.8% and 21.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.02%.
Volatility
TrueBlue's last day, last week, and last month's current intraday variation average was 3.32%, 3.05%, and 1.96%, respectively.
TrueBlue's highest amplitude of average volatility was 1.62% (day), 3.08% (last week), and 2.55% (last month), respectively.
TrueBlue's Stock Yearly Top and Bottom Value
TrueBlue's stock is valued at $26.83 at 00:22 EST, way under its 52-week high of $32.91 and way higher than its 52-week low of $16.66.
TrueBlue's Moving Average
TrueBlue's worth is below its 50-day moving average of $29.35 and below its 200-day moving average of $27.77.5. Chesapeake Utilities Corporation (CPK)
9.7% sales growth and 12.06% return on equity
Chesapeake Utilities Corporation operates as an energy delivery company.
Chesapeake Utilities Corporation's sales growth this year is expected to be 15% and 11.2% for next year.
Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 546.64M for the twelve trailing months.
Volume
Today's last reported volume for Chesapeake Utilities Corporation is 38787 which is 26.32% below its average volume of 52644.
Chesapeake Utilities Corporation's sales growth for the next quarter is 9.7%. The company's growth estimates for the present quarter and the next is 4% and 4.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.06%.
Volatility
Chesapeake Utilities Corporation's last day, last week, and last month's current intraday variation average was 0.69%, 0.83%, and 0.86%, respectively.
Chesapeake Utilities Corporation's highest amplitude of average volatility was 2.28% (day), 1.98% (last week), and 1.94% (last month), respectively.
Chesapeake Utilities Corporation's Stock Yearly Top and Bottom Value
Chesapeake Utilities Corporation's stock is valued at $132.74 at 00:22 EST, below its 52-week high of $146.30 and way higher than its 52-week low of $99.64.